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Abstract: Obesity is supposed to cause renal injury via autophagy deficiency. Recently, sodium glucose
co-transporter 2 inhibitors (SGLT2i) were reported to protect renal injury. However, the mechanisms of
SGLT2i for renal protection are unclear. Here, we investigated the effect of SGLT2i for autophagy in
renal proximal tubular cells (PTCs) on obesity mice. We fed C57BL/6J mice with a normal diet (ND) or
high-fat and -sugar diet (HFSD) for nine weeks, then administered SGLT2i, empagliflozin, or control
compound for one week. Each group contained N = 5. The urinary N-acetyl-beta-d-glucosaminidase
level in the HFSD group significantly increased compared to ND group. The tubular damage was
suppressed in the SGLT2i–HFSD group. In electron microscopic analysis, multi lamellar bodies that
increased in autophagy deficiency were increased in PTCs in the HFSD group but significantly
suppressed in the SGLT2i group. The autophagosomes of damaged mitochondria in PTCs in the
HFSD group frequently appeared in the SGLT2i group. p62 accumulations in PTCs were significantly
increased in HFSD group but significantly suppressed by SGLT2i. In addition, the mammalian
target of rapamycin was activated in the HFSD group but significantly suppressed in SGLT2i group.
These data suggest that SGLT2i has renal protective effects against obesity via improving autophagy
flux impairment in PTCs on a HFSD.
Keywords: sodium glucose co-transporter 2 inhibitor; mammalian target of rapamycin (mTOR);
autophagy; obesity; multi lamellar body
1. Introduction
Much attention was focused on the associations between obesity/metabolic syndrome (MetS) and
kidney injury recently. In large-cohort studies, high body mass index was shown to be a risk factor for
end-stage renal diseases independently compared to hypertension or diabetes [1]. Many researches
were conducted on the mechanisms of kidney injury by obesity/MetS. In addition, autophagy deficiency
is reported to be one of the renal injury causes [2]. Autophagy contributes to cellular homeostasis
by promoting degradation and recycling of intracellular defective macromolecules and organelles,
while autophagy deficiency leads to cellular death. Autophagy deficiency is observed in renal proximal
tubular cells (PTCs) of obesity patients [2]. In addition, autophagy flux impairment by lysosomal
dysfunction, inflammasome activation, and macrophage invasion was observed in PTCs of obesity
mice [3]. Thus, autophagy deficiency is believed to be involved in kidney injury by obesity/MetS.
Recently, sodium glucose co-transporter 2 inhibitor (SGLT2i), belonging to a class of medications
used for the treatment of type II diabetes mellitus via inhibiting reabsorption of glucose in PTCs
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and, therefore, lowering blood sugar, was reported to have renal protective effects in chronic kidney
disease patients [4]. SGLT2i was reported to ameliorate glomerular hyperfiltration by normalization of
tubuloglomerular feedback [5], as well as to improve the mitochondrial abnormalities in PTCs and to
reduce the oxidative stress [6,7]. Effects of SGLT2i with respect to autophagy in the kidney were also
researched; however, the results are controversial [8,9]. In this study, we investigated the therapeutic
effect of SGLT2i on autophagy deficiency in PTCs of obesity mice.
2. Results
2.1. Effects of SGLT2i on Clinical Parameters in Mice
We measured physiological and metabolic parameters of four groups of mice as described in
Figure 1 to determine the effect of SGLT2i for obesity-related renal injury (Table 1). Mice fed a high-fat
and -sugar diet (HFSD) showed a significant increase in body weight compared to mice fed a normal
diet (ND). HFSD-fed mice also showed a significant increase in systolic blood pressure and serum total
cholesterol compared to ND-fed mice. Serum creatinine of HFSD-fed mice was also a little higher than
that of ND-fed mice; however, blood urea nitrogen of HFSD-fed mice showed no significant increase
compared to that of ND-fed mice. These data suggest that there was no significant difference in renal
function between these two groups. SGLT2i administration significantly increased the amount of urine
glucose in both ND-fed and HFSD-fed mice. Among HFSD-fed mice, blood glucose and serum total
cholesterol levels in the SGLT2i-treated group were significantly lower than those in HFSD group
mice. These results are consistent with reports of clinical researches which examined the lowering
effects of blood glucose and serum total cholesterol [10]. However, there was no significant difference
in bodyweight between the SGLT2i-treated group and the control group of HFSD-fed mice.
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Figure 1. Physiological and metabolic parameters in normal diet (ND)-fed group and high-fat and
-sugar diet (HFSD)-fed group. Results are presented as the mean ± standard deviation. Differences were
evaluated by two-way ANOVA followed by Tukey–Kramer test; * p < 0.05 vs. control ND, # p < 0.05 vs.
control HFSD. SGLT2i: empagliflozin.
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Table 1. Physiological and metabolic parameters in normal diet (ND)-fed group and high-fat and
-sugar diet (HFSD)-fed group. Results are presented as the mean ± standard deviation. Differences were
evaluated by two-way ANOVA followed by Tukey–Kramer test; * p < 0.05 vs. control ND, # p < 0.05 vs.
control HFSD. SGLT2i—sodium glucose co-transporter 2 inhibitor: empagliflozin.
Control ND SGLT2i ND Control HFSD SGLT2i HFSD
Body Weight (g) 24.40 ± 1.37 26.44 ± 1.25 31.45 ± 1.56 * 29.90 ± 0.85
Systolic blood pressure (mmHg) 101.4 ± 9.0 101.0 ± 11.5 120.6 ± 7.7 * 109.2 ± 4.1
Diastolic blood pressure (mmHg) 76.0 ± 12.0 65.8 ± 12.8 73.0 ± 11.5 75.8 ± 5.3
Urine glucose (mg/day) 7.8 ± 8.8 294.2 ± 65.6 * 1.1 ± 1.6 269.1 ± 39.3 #
Blood glucose (mg/dL) 256.6 ± 24.0 268.8 ± 37.1 308.8 ± 61.5 204.6 ± 27.8 #
Total cholesterol (mg/dL) 79.8 ± 3.2 89.6 ± 8.3 138.2 ± 16.8 * 113.0 ± 9.3 #
Triglycerides (mg/dL) 35.8 ± 8.8 31.4 ± 6.2 38.4 ± 24.1 25.0 ± 6.6
Glycoalbumin (%) 2.48 ± 0.69 2.74 ± 0.42 3.32 ± 0.42 2.80 ± 0.95
Serum creatinine (mg/dL) 0.088 ± 0.008 0.088 ± 0.013 0.120 ± 0.027 * 0.112 ± 0.013
Blood urea nitrogen (mg/dL) 23.54 ± 1.86 21.42 ± 1.85 17.18 ± 6.42 15.72 ± 3.33
2.2. SGLT2i Decreased Lipid Accumulation in PTCs of Obesity Mice
To evaluate the kidney injury, we performed periodic acid–Schiff staining on kidney sections.
No glomerular injury lesion or expansion was observed in HFSD-fed mice kidney (Figure 2A(c)),
and interstitial inflammation was not noticeable. Vacuoles appeared in the PTCs of HFSD-fed mice
(Figure 2A(g)), and SGLT2i significantly decreased these vacuoles (Figure 2B). These vacuoles were
positive with toluidine blue staining, which detects phospholipids (Figure 2A(k,l)). PTCs of HFSD-fed
mice were also positive with oil red O staining, which detects neutral triglycerides and lipids
(Figure 2A(o)), although less clear than with toluidine blue staining. These results suggest that SGLT2i
could decrease lipid accumulation in PTC, consistent with other reports which examined the effect of a
four-week administration of SGLT2i on the lipid accumulation of PTCs [11].Fig. 2 
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Figure 2. SGLT2 inhibitor (SGLT2i) decreased lipid accumulation in renal proximal tubular cells
(PTCs). (A) Light microscope analysis of kidney sections. Periodic acid–Schiff (PAS) staining of (a–d)
glomerular and (e–h) proximal tubules; (i–l) toluidine blue staining of kidney sections; (m–p) oil red
O staining of kidney sections. (B) Quantitative analysis of vacuole area in PTCs; arrow: vacuoles in
PTCs; arrowhead: oil red O-positive area. Results are presented as the mean ± standard deviation.
Differences were evaluated by two-way ANOVA followed by Tukey–Kramer test (* p < 0.05); bars:
25 µm (A). SGLT2i: empagliflozin.
2.3. SGLT2i Decreased p62 Accumulation on PTCs in Obesity Mice
To evaluate autophagy flux in PTCs, we performed immunostaining of p62 on kidney
sections. p62 binds to cytoplasmic bodies which are degraded by autophagy—such as damaged
mitochondria, ubiquitinated proteins, and so on—and p62 ccumulation is reported to increase in
overnutrition d seases such as MetS and iabe s mellitus because of autophagy flux impai men [2].
p62 accumulations in PTCs of HFSD-fed mice were significantly increas d compared with those n
PTCs of ND-fed mice (Figure 3A,B). Among HFSD-fed mice, p62 accumulation in the SGLT2i-treated
group was significantly lower than that in the control group (Figure 3B).
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We also performed p62 immunostaining on LLC-PK1 cells. p62 accumulation was significantly
increased when exposed to high glucose (25 mM) or palmitic acid (250 µM), and SGLT2i significantly
decreased this p62 accumulation in LLC-PK1 cells exposed to high glucose or high glucose plus palmitic
acid, but not significantly in those exposed to palmitic acid only (Figure 4).
These results suggest that SGLT2i promoted the degradation of p62 accumulation mainly via
protecting PTCs from high glucose exposure.
2.4. SGLT2i Decreased Autolysosomes and Increased Autophagosomes in PTCs of Obesity Mice
Next, we performed ultrastructural analysis in PTCs by transmission electron microscopy to
morphologically evaluate autophagy flux. Large-size residual bodies—around 3 to 6 µm in diameter,
almost all of which were multi lamellar bodies (MLBs)—appeared in PTCs of HFSD-fed mice (Figure 5A).
MLBs are reported to appear in PTCs of obesity mice as a result of lysosomal dysfunction, filled with
phospholipids, and they have a lysosomal/autophagic origin (autolysosomes) [3]. The phospholipids
in MLBs are supposed to originate from degraded organelles such as damaged mitochondria [2].
Most MLBs in this study had morphological characteristics of the autolysosome, with segregated
organelles losing their distinct shape and acid phosphatase activity (black deposits) indicating that fusion
with lysosomes occurred [12,13]. In addition to MLBs, mitochondrial damage (swelling, inner membrane
disarrangement) also appeared in PTCs of HFSD-fed mice (Figure 5C). Damaged mitochondria are reported
to appear in PTCs on obesity mice followed by reactive oxygen species generation or inflammasome
activation [2,7]. Interestingly, the number and size of MLBs in HFSD-fed mice of the SGLT2i-treated group
were significantly lower than those of the control group (Figure 5B). These data suggest that SGLT2i
improved the lysosomal function of HFSD-fed mice. Moreover, mitophagosomes—autophagosomes
of damaged mitochondria, morphologically characterized by double-membrane vacuoles delimitating
non-degradative mitochondria [12,13]—appeared in PTCs of HFSD-fed mice treated with SGLT2i
(Figure 5D). These results suggest that SGLT2i restored autophagy flux [14].
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in renal pr xi al tubul r cells (PTCs) of obesity mice. (A) PTCs in transmissio electron microscopy
images; arrowhead: MLBs; bars: 10 µm. (B) Quantitative analysis of residual bodies in PTCs. Results are
presented as the mean ± standard deviation. Differences were evaluated by two-way ANOVA followed by
Tukey–Kramer test (* p < 0.05). (C) Mitochondria in PTCs of transmission electron microscopy images;
bars: 1.0 µm. (D) Mitophagosomes in PTCs of HFSD-fed mice treated with SGLT2i; bars: 500 nm.
SGLT2i: empagliflozin.
We also performed ultrastructural analysis in LLC-PK1 cells. Mitochondria damage was reported
to occur in PTCs exposed to high glucose or palmitic acid [2,15]. Consistent with these reports,
damaged mitochondria appeared together with a lot of residual bodies—most of which were showing
the morphological characteristics of MLBs and/or autolysosomes—in LLC-PK1 cells exposed to
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high glucose or palmitic acid (Figure 6s–x). Larger MLBs than in other groups—around 5 µm in
diameter—appeared in LLC-PK1 cells exposed to both high glucose and palmitic acid (Figure 6g),
indicating the synergistic effect of high glucose and palmitate acid. Lipid droplets appeared in LLC-PK1
cells exposed to palmitic acid (Figure 6u,v), but not apparently in those exposed to high glucose only.
Moreover, mitophagosomes appeared in SGLT2i-administered LLC-PK1 cells exposed to high glucose
or high glucose plus palmitic acid (Figure 6y,z).Int. J. Mol. Sci. 2020, 21, x 10 of 17 
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Figure 6. SGLT2 inhibitor (SGLT2i) increased autophagosomes of damaged mitochondria in LLC-PK1 cells.
(a–h) Cytoplasm of LLC-PK1 cell; arrowhead: residual bodies; bars: 2.0 µm. (i–p) Representative images
of residual bodies; bars: 500 nm. (q–x) Representative images of mitochondria; asterisk: lipid droplets;
bars: 500 nm. (y,z) Representative images of mitophagosomes; bars: 500 nm. SGLT2i: empagliflozin.
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Taken together, SGLT2i ameliorates lysosomal dysfunction of obesity mice by mainly protecting
PTCs from high glucose exposure, resulting in autophagy flux improvement.
2.5. SGLT2i Suppressed Mammalian Target of Rapamycin (mTOR) Activation in PTCs of Obesity Mice
Next, we examined the change in mTOR activation by SGLT2i. In overnutrition, mTOR is
activated by glucose, insulin signal, or amino acids, before forming mTOR signaling complex 1
(mTORC1), which inhibits the transcription of lysosomal enzymes [16] and inhibits autophagosome
formation [17]. mTORC1 also increases lipid synthesis and deposition in lysosome, resulting in
lysosomal dysfunction [3,18,19]. In this study, we measured the expression of mTOR phosphorylated
on serine 2448 (mTOR (pS2448)), which is predominantly contained in mTORC1 [20] and one of the
indexes of mTOR activation. The expression of mTOR (pS2448) in the kidney was significantly higher
in HFSD-fed mice compared to that in ND-fed mice (Figure 7). Among HFSD-fed mice, the expression
of mTOR (pS2448) in the SGLT2i-treated group was significantly lower than that in the control group
(Figure 7). These data suggest that SGLT2i could improve autophagy flux impairment in PTCs on
obesity mice via suppression of mTOR activation.
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Figure 7. SGLT2 inhibitor (SGLT2i) suppressed mammalian target of rapamycin (mTOR) activation in renal
proximal tubular cells of obesity mice. Western blotting analysis for mTOR phosphorylated on serine 2448
(mTOR (pS2448) of the kidney. Results are presented as the mean ± standard deviation. Differences were
evaluated by two-way ANOVA followed by Tukey–Kramer test (* p < 0.05). SGLT2i: empagliflozin.
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2.6. SGLT2i Decreased the Amount of Urinary NAG of Obesity Mice Independent of Urinary Proteins
We evaluated urinary N-acetyl-β-d-glucosaminidase (NAG) for tubulointerstitial damage in
obesity. Urinary NAG—a lysosomal hydrolase primarily originating from PTCs—is a marker of
proximal tubular injury [21,22]. The amount of urinary NAG in HFSD-fed mice was significantly
higher than that in ND-fed mice (Figure 8). Among HFSD-fed mice, urinary NAG in the SGLT2i-treated
group was significantly lower than that in the control group (Figure 8A). However, we could not
observe significant differences in urinary protein (Figure 8B), and there was no glomerular expansion
or lesion in HFSD-fed mice of our study, as noted above (Figure 2A). It is important to note that urinary
protein could affect the amount of urinary NAG, as the absorption of urinary protein into PTCs could
cause nuclear factor-kappa B activation, inflammation, and tubular injury [23]. These data suggest that
SGLT2i could directly protect PTCs independent of the effects on tubulo-glomerular feedback.Fig. 8 
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Figure 8. SGLT2 inhibitor (SGLT2i) decreased the amount of urinaryN-acetyl-beta-d-glucosaminidase (NAG)
independent of urinary proteins. The amount of (A) urinary NAG and (B) protein. The urine was collected
for 24 h one day before sacrifice. Results are presented as the mean ± standard deviation. Differences were
evaluated by two-way ANOVA followed by Tukey–Kramer test (* p < 0.05). SGLT2i: empagliflozin.
3. Discussion
Several renal protective mechanisms of SGLT2i were reported; however, the effect of SGLT2i
on autophagy was not elucidated. In this study, we found that SGLT2i has a therapeutic effect on
autophagy flux impairment in PTCs on obesity mice. These findings might contribute to elucidating
the renal protective mechanism of SGLT2i in obesity patients.
We focused on lysosomal functions as a target of SGLT2i for improving autophagy flux impairment
in PTCs. Lysosomes fuse with autophagosomes to form autolysosomes, and they play an important
role in degradation process of autophagy. In obesity, lysosomal hydrolase is inactivated by the
pH increase caused by lipid accumulation in the lysosome, resulting in impairment of lysosomal
capacity and autophagy flux [3]. Autolysosomes, the degradation capacity of which is impaired by
lipid accumulation, are reported to form MLBs in obesity mice [3]. Our findings, i.e., the decrease
of autolysosomes and the increase of mitophagosomes after SGLT2i administration, suggest the
therapeutic effect of SGLT2i on lysosomal dysfunction and autophagy flux impairment in PTCs.
We considered that these effects are due to the suppression of the activated mTOR as the result of the
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PTC’s decreased exposure of glucose. Activated mTOR forms mTORC1 and inhibits the transcription
of lysosomal enzymes [16], as well as increases lipid deposition in lysosome, resulting in lysosomal
dysfunction [3,18,19]. In this study, SGLT2i increased the amount of urinary glucose—thus decreasing
the reabsorption of glucose into PTCs—and decreased the amount of serum glucose, suggesting the
PTC’s decreased exposure of glucose, both in apical and basal sides. Moreover, we demonstrated that
SGLT2i suppressed mTOR activation in obesity mice. Furthermore, our in vitro study showed that
SGLT2i significantly improved autophagy flux of PTCs exposed to high glucose. These data suggest
that the decrease of glucose influx into PTCs by SGLT2i could directly affect mTOR activation in PTCs.
Our study has at least two limitations. One is that we could not definitively distinguish SGLT2i’s
effect for glucose and lipid metabolism in protecting PTCs; SGLT2i might have protected PTCs by
also improving the lipid metabolism, resulting in amelioration of lipotoxicity in PTCs. In our in vivo
study, SGLT2i administration at least showed no significant difference in bodyweight in obesity mice,
indicating no significant difference in body fat. Furthermore, our in vitro study suggests that PTC’s
protective effect of SGLT2i by inhibiting glucose absorption is independent of lipid exposure. The other
limitation is that SGLT2i might have effects on autophagy of PTCs via other mechanisms. SGLT2i is
reported to have effects on various factors related to autophagy, such as serum insulin, insulin-like
growth factor-1, and sirtuin 1 [17,24,25]. Further studies are needed to elucidate more deeply how
SGLT2i affects the autophagy pathway in PTCs.
It is important to note that SGLT2i showed protective effects of PTCs in obesity mice showing no
significant increase in serum glucose compared to control mice in this study. Similarly, there is a report
which showed SGLT2i’s protective effect of PTC’s mitochondria of obesity mice, which showed no
significant elevation of serum glucose [7]. These findings indicate that over-intake of sugar might cause
glucotoxicity of PTCs in obesity mice even if there is no increase of serum glucose, and urinary glucose
might have an important role in PTC’s glucotoxicity. Unlike most types of cells which take in glucose
only for their energy consumption, PTCs must reabsorb much urinary glucose for the whole body’s
survival and, thus, might be under stronger exposure than other types of cells. In fact, reabsorption of
urinary glucose in proximal tubules plays an important role in the progression of tubular injuries in
diabetic nephropathy [26]. Further studies are needed to elucidate deeply whether urinary glucose
reabsorption could worsen PTC’s injuries in obesity.
There is also a report which concluded that SGLT2i has no sufficient effect on autophagy in PTCs.
Tanaka et al. reported that autophagy insufficiency in the tubular cells of diabetic mice was ameliorated
by food-intake restriction, but not by SGLT2i [9]. They reported that the results were because the effect
of SGLT2i on calorie balance is weaker than that of food-intake restriction; in their study, the amount of
food intake and the bodyweight increase of the SGLT2i-treated group were greater than those in the
control group. This might be because of an appetite increase via the glucose-lowering effect of SGLT2i.
The change in the bodyweight by SGLT2i administration in their study was contrary to that in clinical
trials, where SGLT2i significantly decreased the bodyweight in humans [10]. These reports suggest
that free feeding of mice could mask the effect of SGLT2i on autophagy, and that the adjustment of
food intake is needed to accurately evaluate the autophagy activity in in vivo experiments.
In conclusion, our study suggests that SGLT2i might ameliorate proximal tubular injuries in
obesity via improving autophagy flux impairment.
4. Materials and Methods
4.1. Animal Models
This study was approved by the animal care and use committee of Okayama University
(OKU-2018206). We used five-week-old male mice with a C57BL/6J genetic background (Charles River,
Cologne, Germany). The mice were fed with normal diet with the composition of 13 kcal% fat (Cat#: MF,
Oriental Yeast Co., ltd, Tokyo, Japan) or high-fat diet with the composition of 40 kcal% fat and 40 kcal%
sucrose (Cat#: D12327, Research Diets INC, New Brunswick, USA). After nine weeks of feeding,
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we administrated 10.0 mg/kg SGLT2i (empagliflozin provided from Boehringer-Ingelheim, Ingelheim,
Germany) dissolved with 0.5% hydroxypropyl methylcellulose (HPMC) or 0.5% HPMC (as control)
orally for one week. After that, the mice were sacrificed, and the serum plasma, urine (collected for
24 h), and kidneys were obtained.
4.2. Cell Culture
LLC-PK1 cells (an epithelial cell line originated in proximal tubular cells of porcine kidney) were
cultured in Medium 199 (M4530; Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal
bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin at 37 °C in 5% CO2. When 80% confluent,
the cells were serum-starved by culture in 0.1% fetal bovine serum for 24 h, then exposed to 5.5 mM
glucose or 25 mM glucose in the presence or absence of 500 nM SGLT2i for up to 48 h before harvesting.
Then, 24 h after culture initiation, the medium was changed and 250 µM palmitic acid (P0500;
Sigma-Aldrich, St. Louis, MO, USA) dissolved in 99% chloroform (Wako Pure Chemical Industries,
Ltd., Osaka, Japan) or 99% chloroform (as control) was added.
4.3. Histopathological Analysis
Sections were cut to 4 µm thickness from 10% formalin-fixed paraffin-embedded kidney samples.
These sections were used for periodic acid–Schiff staining. Frozen sections that were cut to 8 µm
thickness were used for oil red O staining of neutral lipid (cholesterol esters and triglycerides) deposits
and immunostaining. For toluidine blue staining of phospholipid deposits, kidney specimens and
LLC-PK1 cells were fixed with 2.5% glutaraldehyde.
For immunofluorescence microscopy, frozen sections (4 µm) and LLC-PK1 cells were stained
using anti-p62 antibody (Cat #: PM066, Medical & Biological Laboratories Co., Ltd., Nagoya, Japan),
anti-aquaporin 1 antibody (Cat #: AQP-001, Alomone labs, Jerusalem, Israel), anti-SGLT2 antibody
(sc-47402; Santa Cruz Biotechnology, Dallas, TX, USA), and/or 4′,6-diamidino-2-phenylindole (DAPI).
Sections were examined using an Olympus FSX100 biological microscope (Olympus Corporation,
Tokyo, Japan). In a kidney histological quantitation, a minimum of six non-overlapping images of
cortex per kidney were observed under 400×magnification.
For electron microscopy, kidney specimens and LLC-PK1 cells were fixed with 2.5% glutaraldehyde
and observed using a transmission electron microscope (H- 7650, Hitachi, Tokyo, Japan).
Quantitative computer-assisted image analysis was performed using a digital image-analyzing
software, ImageJ (available at http://rsbweb.nih.gov/ij/index.html; National Institutes of Health).
4.4. Western Blot Analysis
Proteins were extracted using a lysis buffer (Cat #: 89900, Thermo Fisher Scientific, Inc.,
Waltham, MA, USA) containing a protease inhibitor (Cat #: G652A, Promega Corporation, Fitchburg,
WI, USA) and a phosphatase inhibitor (Cat #: ab201113, Abcam plc., Cambridge, UK), then quantified
using a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific Inc., Waltham, MA, USA).
Equal amounts of protein were separated using 10% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and electrophoretically transferred onto nitrocellulose membranes, which were blocked
with 1% bovine serum albumin (Cat #: A7888-50G, Sigma-Aldrich Co. LLC, St. Louis, MO, USA) for 30 min.
The membranes were incubated with the following primary antibodies overnight at 4 ◦C: anti-phospho
mTOR (1:1,000, Cat #: 2971, Cell Signaling Technology, Danvers, MA, USA) and anti-glyceraldehyde
3-phosphate dehydrogenase (GAPDH; 1:10,000, Cat #: 2118, Cell Signaling Technology, Danvers, MA,
USA). They were incubated with a horseradish peroxidase (HRP)-conjugated secondary antibody (1:2,000,
Cat#: 170-6515, Bio-Rad Laboratories, Inc., Hercules, CA, USA) for 1 h. The membranes were extensively
washed in phosphate-buffered saline with Tween-20, and antigen–antibody complexes were visualized
by chemiluminescence using an enhanced chemiluminescence (ECL) kit (ECLTM Prime Western Blotting
Reagents, GE Healthcare, Chicago, IL, USA).
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4.5. Statistical Analysis
Results are presented as the mean ± standard deviation. Differences were evaluated by two-way
ANOVA followed by Tukey–Kramer test (JMP® 13.2, SAS Institute INC, Cary, USA). Statistical significance
was accepted at the p < 0.05 level.
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Abbreviations
HFSD high-fat and -sugar diet
HPMC hydroxypropyl methylcellulose
Mets metabolic syndrome
MLBs multi lamellar bodies
mTOR mammalian target of rapamycin
mTORC1 mTOR signaling complex 1
NAG N-acetyl-β-d-glucosaminidase
ND normal diet
PA palmitic acid
pS2448 phosphorylated on serine 2448
PTCs proximal tubular cells
SGLT2i sodium glucose co-transporter 2 inhibitor
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